Compare · APGE vs ARGX
APGE vs ARGX
Side-by-side comparison of Apogee Therapeutics Inc. (APGE) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APGE and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.51B, about 8.6x APGE ($6.24B).
- Over the past year, APGE is up 104.2% and ARGX is up 56.1% - APGE leads by 48.1 points.
- APGE has been more active in the news (7 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 19 for APGE).
- Company
- Apogee Therapeutics Inc.
- argenx SE
- Price
- $86.68+4.91%
- $897.53+4.16%
- Market cap
- $6.24B
- $53.51B
- 1M return
- +4.60%
- +10.36%
- 1Y return
- +104.24%
- +56.11%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2017
- News (4w)
- 7
- 5
- Recent ratings
- 19
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest APGE
- Chief Medical Officer Dambkowski Carl exercised 4,125 shares at a strike of $22.86 and sold $432,905 worth of shares (5,500 units at $78.71) as part of a pre-agreed trading plan, decreasing direct ownership by 0.66% to 205,648 units (SEC Form 4)
- Apogee Therapeutics to Participate in Upcoming June Conferences
- Apogee Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Apogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
- Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
- Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
- Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
- Chief Executive Officer Henderson Michael Thomas sold $1,641,711 worth of shares (20,000 units at $82.09) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,115,987 units (SEC Form 4)
- SEC Form 144 filed by Apogee Therapeutics Inc.
- SEC Form 10-Q filed by Apogee Therapeutics Inc.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference